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RATIONALE: Since 1988 numerous AIT-guidelines (AIT-GLs) have
been developed by national and international organizations to guide
physicians in AIT. Even so, AIT is still severely under-used. AGREE-II
was developed in 2010 byMcMaster university methodologists to evaluate
guideline quality.
METHODS: The project team consisted of allergists, knowledgable in
AIT, trained in AGREE II, with methodologist’s guidance. AIT-GLs in any
languagewere sought from 1980-today inMedline, Embase and contacting
local AIT experts; AIT-GLs were AGREE II evaluated by 2 independent
reviewers; discrepancies were resolved in a 2nd round, by team-discussion
or methodologists’ consulting.
RESULTS: We found 31 AIT-GLs (16 post-2010), ranging from local
consensus reports to international position papers (EAACI, AAAAI-
ACAAI, WAO). Pre-2010 GLs’ score ranged 1.6-5.2/7 and post-2010
GLs’ 1.6-6/7. The best evaluations went to the German AIT-GL (6.0)
followed by the AAAAI/ACAAI (5.2) and the Mexican GL (5.1). These
were the also the only 3 GLs that received ‘yes’ of both evaluators to the
last item: ‘I would recommend this GL for use’. The domains of
Stakeholder involvement and Rigor of Development only scored 3/7, but
Domain ‘Applicability’ scored the lowest. Strikingly, newer guidelines
only scored better in ‘Editorial Independence’ and ‘Global evaluation’.
CONCLUSIONS: In AIT-GLs there is still a lot of room for improvement,
especially in two domains, crucial in dissemination (stakeholder involve-
ment and applicability). For some the ‘Scientific rigor’ domain flawed. In
situations with limited resources, transculturizing a high-quality existing
GL might be appropriate. AGREE-II could help to pick quality candidate
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RATIONALE: One of the described benefits of allergen specific subcu-
taneous immunotherapy (SCIT) is its potential effect on the reduction of
the medication needed for the treatment of allergic diseases. Our aim is toassess the reduction of inhaled corticosteroids (ICS) in children with
asthma under SCIT.
METHODS: A retrospective study was conducted, obtaining data from
asthma patients9medical records of a regional allergy center in Monterrey,
Mexico, from March 2015 to March 2016. Two age groups were
considered and ICS was reviewed before and six months after starting
SCIT.
RESULTS: 169 patients were included. In the first group (N5128; 5-11
years old), 57.8%were treated with SCIT, of which 37.8% never used ICS.
From the patients (42.2%) who used ICS, 14.9% continued them and
41.9% quitted them 6 months after the SCIT onset (p50.24). The
proportion of patients who discontinued ICS after 6 months was higher
in the group receiving SCIT (p50.002). In the second group (N541; 12-18
years old), 73.2% were treated with SCIT, 73.3% of the patients used ICS,
of which 16.6% continued them and 56.6% discontinued them 6 months
after the SCIT onset (p50.29). There was no difference between patients
under SCIT with ICS and the patients who discontinued them (p50.48).
Other allergic comorbidities found were: allergic rhinitis (AR) (92.3%),
AR and atopic dermatitis (AD) (6.5%), AR and food allergy (0.6%), and
AD (0.6%).
CONCLUSIONS: Reduction in the need for ICS was higher in children
under 11 years old receiving SCIT compared with patients who did not
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RATIONALE: Investigation the synergistic effect of synbiotic in clinical
and immunologic efficacy of subcutaneous allergen immunotherapy in
allergic rhinitis patients.
METHODS: Twenty- eight individuals aged between 5-55 years with
allergic rhinitis were enrolled in a double blind, placebo controlled study.
All patients who met the eligibility criteria were randomly divided into
three groups: A) Immunotherapy+ synbiotic, B) Immunotherapy+ placebo
and C) just synbiotic. Group A and C participants received 1 synbiotic
capsule per day during the first two months of treatment. Participants
underwent clinical and laboratory assessment in week 8, and at the end of
intervention, month 6.
RESULTS: improvement in symptom score and quality of life were
occurred in all groups, yet there was no significant difference between
groups A vs. B (P value5 >0.99) after 6 month of treatment and neither
between groups A vs. C (P value50.25) after 2 month of treatment. In
immunologic parameters, there were significant enhancement in T helper
type 1 cell percentage in groupA rather than group B (P value5 0.022) and
also in group A rather than group C (P value5 0.023. There was also no
significant difference between groups B vs. C (P value5 0.85).
CONCLUSIONS: in this study we conclude that adding symbiotic to
SCIT increase TH1 cells percentage although this effect is temporary. there
was no significant statistically difference in clinical response among the
groups. Future studies with large sample size could possibly make this
difference statistically significant.
